ErianinCAS# 95041-90-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 95041-90-0 | SDF | Download SDF |
| PubChem ID | 356759 | Appearance | White powder |
| Formula | C18H22O5 | M.Wt | 318.36 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | DMSO : 125 mg/mL (392.64 mM; Need ultrasonic) | ||
| Chemical Name | 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol | ||
| SMILES | COC1=C(C=C(C=C1)CCC2=CC(=C(C(=C2)OC)OC)OC)O | ||
| Standard InChIKey | UXDFUVFNIAJEGM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H22O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h7-11,19H,5-6H2,1-4H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Erianin, often used as an antipyretic and analgesic agent, it also has antiangiogenic action by inhibiting endothelial metabolism in a JNK/SAPK-dependent manner and inducing endothelial cytoskeletal disorganisation. |
| Targets | PARP | Bcl-2/Bax | Caspase | JNK | SAPK | ATP |
| In vitro | ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities.[Pubmed: 21997795]Invest New Drugs. 2012 Oct;30(5):1899-907.ZJU-6 was designed to enhance anti-angiogenesis and anti-tumour activity of its parent compound Erianin, a clinic anti-tumour agent. This study investigated the detailed biological mechanism of ZJU-6 in comparison with that of Erianin.
Erianin induces apoptosis in human leukemia HL-60 cells.[Pubmed: 11749794]Acta Pharmacol Sin. 2001 Nov;22(11):1018-22.To investigate the effect of Erianin on human HL-60 cell line and explore its mechanism of apoptosis in vitro.
|
| In vivo | In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent.[Pubmed: 15196540]Eur J Cancer. 2004 Jul;40(10):1554-65.This study evaluated the anti-angiogenic activities of Erianin in vivo and in vitro.
|
| Kinase Assay | Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells.[Pubmed: 15113050]In Vivo. 2004 Mar-Apr;18(2):223-8.Erianin is a natural product derived from Dendrobium chrysotoxum, with promising antitumor activity. |
Erianin Dilution Calculator
Erianin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1411 mL | 15.7055 mL | 31.411 mL | 62.822 mL | 78.5275 mL |
| 5 mM | 0.6282 mL | 3.1411 mL | 6.2822 mL | 12.5644 mL | 15.7055 mL |
| 10 mM | 0.3141 mL | 1.5705 mL | 3.1411 mL | 6.2822 mL | 7.8527 mL |
| 50 mM | 0.0628 mL | 0.3141 mL | 0.6282 mL | 1.2564 mL | 1.5705 mL |
| 100 mM | 0.0314 mL | 0.1571 mL | 0.3141 mL | 0.6282 mL | 0.7853 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Pyrolin
Catalog No.:BCN6902
CAS No.:95-71-6
- 2-(Morpholinodithio)benzothiazole
Catalog No.:BCC8484
CAS No.:95-32-9
- 2-Benzothiazolyl diethyldithiocarbamate
Catalog No.:BCC8558
CAS No.:95-30-7
- Chlorzoxazone
Catalog No.:BCC4650
CAS No.:95-25-0
- 2-Amino-6-chlorobenzothiazole
Catalog No.:BCC8539
CAS No.:95-24-9
- 5-Amino-1,3-dihydro-2H-benzimidazol-2-one
Catalog No.:BCC8728
CAS No.:95-23-8
- Thianaphthene
Catalog No.:BCC9178
CAS No.:95-15-8
- Quercetin-3-o-rutinose
Catalog No.:BCN3404
CAS No.:949926-49-2
- Gypenoside XLIX
Catalog No.:BCN1207
CAS No.:94987-08-3
- 6-Methoxynaringenin
Catalog No.:BCN4500
CAS No.:94942-49-1
- 8-Hydroxy-ar-turmerone
Catalog No.:BCN7513
CAS No.:949081-09-8
- 6-(4-Hydroxy-3-methylphenyl)-2-methylhept-2-en-4-one
Catalog No.:BCN7514
CAS No.:949081-05-4
- Liproxstatin-1
Catalog No.:BCC5651
CAS No.:950455-15-9
- Gemcitabine
Catalog No.:BCC3784
CAS No.:95058-81-4
- 6-O-Methacryloyltrilobolide
Catalog No.:BCN7599
CAS No.:950685-51-5
- B-Raf IN 1
Catalog No.:BCC5439
CAS No.:950736-05-7
- PCI-34051
Catalog No.:BCC2148
CAS No.:950762-95-5
- Quizartinib (AC220)
Catalog No.:BCC2548
CAS No.:950769-58-1
- trans-4-Hydroxy-2-nonenoic acid
Catalog No.:BCN7959
CAS No.:95087-42-6
- PF-670462
Catalog No.:BCC1856
CAS No.:950912-80-8
- 2'-Deoxyuridine
Catalog No.:BCC8278
CAS No.:951-78-0
- Boc-N-Me-Tyr-OH.DCHA
Catalog No.:BCC3355
CAS No.:95105-25-2
- Desformylflustrabromine hydrochloride
Catalog No.:BCC7651
CAS No.:951322-11-5
- Artemetin acetate
Catalog No.:BCN4501
CAS No.:95135-98-1
Erianin induces apoptosis in human leukemia HL-60 cells.[Pubmed:11749794]
Acta Pharmacol Sin. 2001 Nov;22(11):1018-22.
AIM: To investigate the effect of Erianin on human HL-60 cell line and explore its mechanism of apoptosis in vitro. METHODS: Inhibition of proliferation was measured with colorimetric MTT assay. The morphologic changes were observed by fluorescence and electron microscopes. DNA fragmentation was visualized by agarose gel electrophoresis, and the DNA degradation was determined by flow cytometry. Immunohistochemical analysis was used to identify the expression of bcl-2 and bax genes. RESULTS: The growth of human HL-60 cells was significantly inhibited by Erianin 20-81.9 nmol/L during 72 h treatment (P < 0.01). The IC50 value was 38 nmol/L after a 24-h exposure to Erianin, while that of vincristine, the positive control, was 101 nmol/L. The typical morphologic changes were observed and the nuclear DNA fragmentation exhibited "ladder" pattern. The cell cycle of HL-60 cells was arrested in G2/M phase, and expression of bcl-2 gene was decreased while that of bax was increased. CONCLUSION: Erianin showed potent inhibitory activity on the proliferation of HL-60 cells. The inhibition might be relative to the apoptosis induced by Erianin and the altered expression of bcl-2 and bax genes in HL-60 cells.
In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent.[Pubmed:15196540]
Eur J Cancer. 2004 Jul;40(10):1554-65.
This study evaluated the anti-angiogenic activities of Erianin in vivo and in vitro. Erianin, a natural product from Dendrobium chrysotoxum, caused moderate growth delay in xenografted human hepatoma Bel7402 and melanoma A375 and induced significant vascular shutdown within 4 h of administering 100 mg/kg of the drug. Erianin also displayed potent anti-angiogenic activities in vitro: it abrogated spontaneous or basic fibroblast growth factor-induced neovascularisation in chick embryo; it inhibited proliferation of human umbilical vein endothelial cells (EC(50) 34.1+/-12.7 nM), disrupted endothelial tube formation, and abolished migration across collagen and adhesion to fibronectin. Erianin also exerted selective inhibition toward endothelial cells, and quiescent endothelium showed more resistance than in proliferative and tumour conditions. In a cytoskeletal study, Erianin depolymerised both F-actin and beta-tubulin, more significantly in proliferating endothelial cells than in confluent cells. In conclusion, Erianin caused extensive tumour necrosis, growth delay and rapid vascular shutdown in hepatoma and melanoma models; it inhibited angiogenesis in vivo and in vitro and induced endothelial cytoskeletal disorganisation. These findings suggest that Erianin has the therapeutic potential to inhibit angiogenesis in vivo and in vitro.
Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of erianin for intravenous injection in dogs.[Pubmed:19402345]
Arzneimittelforschung. 2009;59(3):141-5.
The purpose of the present study was to examine the pharmacokinetic characteristics of Erianin (2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)-ethyl]-phenol, CAS 95041-90-0), a nature product extracted from Dendrobium chrysotoxum, having notable antitumour activity, after intravenous injection of Erianin fat emulsion to beagle dogs. An HPLC-MS method was developed to analyze the Erianin levels in dog plasma and validated in a pharmacokinetic study. Plasma profiles were obtained after intravenous injection of Erianin fat emulsion at the doses 7.5, 15 and 30 mg/kg. The elimination half-life (t(1/2)) values for Erianin were estimated to be 1.41+/- 0.31, 1.66 +/- 0.19, 1.60 0.28 h, while the mean area under concentration-time curve (AUC(0-infinity)) values were 1021.3 +/- 373.7, 2305.1 +/- 597.0 and 3952.1 +/- 378.2 ng x h/ml, respectively. In conclusion, the present observations indicated that Erianin plasma concentrations were clearly dose-proportional for the dose range studied. There was no gender difference in pharmacokinetics for Erianin in male and female dogs.
Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells.[Pubmed:15113050]
In Vivo. 2004 Mar-Apr;18(2):223-8.
BACKGROUND: Erianin is a natural product derived from Dendrobium chrysotoxum, with promising antitumor activity. MATERIALS AND METHODS: To evaluate the metabolic effect of Erianin, a cytosensor assay for acidification rate, MTT assay, measurement of lactate, glucose and ATP were performed in human umbilical vein endothelial cells (HUVECs) exposed to 1-100 nM Erianin. JNK/SAPK activity was detected by Western blot. RESULTS: Twelve- or 24- hour incubation with Erianin induced a dose-dependent metabolic inhibition, as indicated by reduced acidification rate and cell viability, with an endothelium-selectivity. Erianin caused decreases in lactate production, glucose consumption and intracellular ATP level. Pretreatment with the JNK/SAPK inhibitor SP600125 significantly abolished these inhibitory responses, and especially restored the Erianin-induced decreases in ATP and the Erianin-induced phosphorylation of JNK/SAPK with dose- and time- dependence. CONCLUSION: Erianin inhibited endothelial metabolism in a JNK/SAPK-dependent manner. This mechanism may be involved in the potential antitumnor and antiangiogenic actions of Erianin.
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities.[Pubmed:21997795]
Invest New Drugs. 2012 Oct;30(5):1899-907.
ZJU-6 was designed to enhance anti-angiogenesis and anti-tumour activity of its parent compound Erianin, a clinic anti-tumour agent. This study investigated the detailed biological mechanism of ZJU-6 in comparison with that of Erianin. Both ZJU-6 and Erianin substantially reduced cell viability and induced apoptosis in human cancer cell lines. Profound G2/M cell arrest was observed 24 h after treatment of MCF-7 cells with ZJU-6 (>/= 2.5 muM) or Erianin (>/= 0.1 muM); being consistent with mitotic collapse. 0.5 muM of Erianin or ZJU-6 failed to stabilise tubulin. Pre-G1 MCF-7 cell accumulating 24 h post treatment indicated apoptosis. Caspase-3 activity, PARP cleavage and Annexin V + ve /PI -ve populations correlate the apoptotic destiny of cells exposed to either ZJU-6 or Erianin. Furthermore ZJU-6 showed potent anti-angiogenetic property and demonstrated radical scavenging capacity. Due to its potent anti-proliferative, pro-apoptotic and anti-angiogenic activities ZJU-6 is an attractive chemotherapeutic agent to be developed.
